Human albumin specific binding polypeptide and its application
By designing and synthesizing high-affinity human albumin-specific binding peptides to fusion with interferon, the problem of short half-life in vivo is solved, achieving the extension of half-life and the improvement of therapeutic effect.
Patent Information
- Application Number
- CN202411162332.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The prior art is difficult to effectively prolong the half-life of interferon in the body, resulting in frequent drug administration and unstable blood drug concentration, affecting the therapeutic effect.
Design and synthesize human albumin-specific binding peptides with high affinity, and use as a vector to fuse with interferon. The high binding peptide sequences are screened through bioinformatics analysis and chemical synthesis, and expressed in E. coli to construct vectors and fusions. Protein to prolong the half-life of interferon.
It significantly prolongs the half-life of interferon, improves the treatment effect, reduces the frequency of administration, maintains the stability of blood drug concentration, and enhances patient compliance.
Smart Images

Figure CN118666961B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a human albumin-specific binding polypeptide and an application thereof. Background Art
[0002] Human serum albumin (HSA), also known as human albumin, is the most abundant protein in the plasma of living organisms and is responsible for various storage and transportation tasks in the body. Its half-life in the human body can reach 19 days, and it is the main transport carrier in human plasma. Directly coupling drug peptides or proteins to HSA, or using peptides that can specifically bind to HSA to fuse with protein drugs to extend the half-life of drug peptides or protein drugs in the body, is an important research strategy to extend the half-life of molecular drugs in the body.
[0003] Not only can HSA fusion technology effectively extend the half-life of protein drugs, but adhesion to HSA is also a new strategy for prolonging the effectiveness of protein drugs.
[0004] A small peptide or protein that can adhere to HSA is connected to cytokines, antibodies, antigens, etc., which specifically binds to HSA in plasma to form a larger molecule, thereby extending its half-life.
[0005] Compared with drugs fused to albumin, protein drugs fused to HSA-specific binding peptides have a much smaller molecular weight than the latter, which is more conducive to drug diffusion from plasma to target tissues. For peptide and protein drugs, binding them to HSA through genetic engineering and protein engineering can not only prolong the half-life of the drug, but also maintain its binding properties with the target protein, ensuring the efficacy of the drug.
[0006] Interferon (IFN) is a type of cytokine secreted by receptor cells after human and animal cells are infected by viruses or induced by various factors such as nucleic acids, bacterial endotoxins, and mitogens. According to the differences in the cell types that produce interferon, the physicochemical properties of interferon, and the biological activity of interferon, interferon can be divided into three types: interferon α, interferon β, or interferon γ. Although the functional mechanism of interferon is complex and has not been fully understood, it is known that it regulates the immune system's response to viruses, cancer, and some other external (or infectious) substances. At the same time, it is known that interferon will not directly kill viruses or tumor cells, but it will promote the immune system response and control the function of genes that regulate the secretion of proteins of various cells, thereby inhibiting the growth of tumor cells. As for α-type interferon, it is known that interferon-α can be used to treat hepatitis B and hepatitis C, and interferon-β can be used to treat multiple sclerosis. Further, related studies have reported that interferon-α can enhance STAT-1, STAT-2 and STAT-3 (J Immunol, 187, 2578-2585, 2011), and it activates STAT3 protein in melanoma cells, contributing to the formation of melanoma (Euro J Cancer, 45, 1315-1323, 2009). Further, it is reported that cells treated with interferon-β induce activation of signaling pathways including AKT (Pharmaceuticals (Basel), 3, 994-1015, 2010). Antiviral activity is one of the basic functions of the interferon family. Studies have shown that interferon does not directly neutralize or kill virions, but virions act as inducers of interferon, activate the structural genes of antiviral proteins in cells, induce cells to synthesize antiviral proteins, interfere with viral gene transcription or translation of viral protein components, thereby preventing the formation of infectious viral particles and achieving the purpose of antiviral.
[0007] Prolonging the half-life of the drug in the body, reducing the number of dosing times, maintaining stable blood drug concentrations, reducing adverse reactions, while improving the treatment response rate and improving patient treatment compliance are important development directions for the development of long-acting interferon.
[0008] In view of this, the present invention is proposed. Summary of the invention
[0009] The technical problem to be solved by the present invention is to overcome the deficiencies of the prior art and provide a human albumin-specific binding polypeptide and its application. The human albumin-specific binding polypeptide provided by the present invention has high HSA adhesion, and the specific binding polypeptide can be used as a carrier to increase the half-life of the target protein in vivo.
[0010] In order to solve the above technical problems, the basic concept of the technical solution adopted by the present invention is:
[0011] The first object of the present invention is to provide a human albumin specific binding polypeptide, wherein the amino acid sequence of the human albumin specific binding polypeptide is selected from at least one of the sequences shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3.
[0012] The present invention uses bioinformatics methods to analyze the spatial structural characteristics of the currently disclosed HSA-specific binding proteins or polypeptides and the surface charge of human serum albumin, and designs a series of new polypeptide molecules, which are directly synthesized by chemical synthesis, and then the affinity of the polypeptide molecules to HSA is measured to select HSA-specific binding polypeptides that can bind to HSA with high binding force. After the above steps, 3 polypeptide sequences with high binding force are obtained. The human albumin-specific binding polypeptide (HSA adhesion peptide) provided by the present invention has high HSA adhesion, and the specific binding polypeptide can be used as a carrier to increase the half-life of the target protein in vivo.
[0013] The second object of the present invention is to provide a nucleotide sequence encoding the amino acid sequence of the human albumin-specific binding polypeptide as described above.
[0014] The nucleotide sequence of the human albumin-specific binding polypeptide referred to in this embodiment is any sequence that can encode any of the amino acid sequences of the human albumin-specific binding polypeptides described above.
[0015] In order to express the above-mentioned human albumin-specific binding polypeptide in Escherichia coli, the present invention performs codon optimization according to the codon preference of Escherichia coli, selects suitable codons and codon combinations to encode a polypeptide sequence with high binding ability, thereby further improving the binding ability of the HSA-specific binding polypeptide in Escherichia coli.
[0016] In a further embodiment, the nucleotide sequence of the human albumin-specific binding polypeptide suitable for expression in Escherichia coli includes:
[0017] The nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1 is shown in SEQ ID NO: 4;
[0018] Or, the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:2 is shown in SEQ ID NO:5;
[0019] Or, the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:3 is shown in SEQ ID NO:6.
[0020] This scheme can use one or more of the above three nucleotide sequences that can encode human albumin-specific binding polypeptides to express in E. coli. After many experiments, the present invention changes the bases at the same position to different bases without changing the amino acid sequence, and combines different optimization schemes at each position to artificially synthesize multiple nucleotide sequences encoding HSA-specific binding polypeptides (not listed here one by one), construct vectors for expression, and the results show that although all are optimized using the codon preference of E. coli, the binding force of the expressed human albumin-specific binding polypeptides is also different. After screening, the present invention obtains the HSA-specific binding polypeptide nucleotide sequence suitable for expression in E. coli.
[0021] The third object of the present invention is to provide a biomaterial, wherein the biomaterial comprises any one of the following:
[0022] 1) A vector having one or more nucleotide sequences as described above.
[0023] The vector referred to in the present invention may be an expression vector, a shuttle vector, an integration vector, etc.
[0024] 2) A recombinant bacterium or a recombinant cell, wherein the recombinant bacterium or the recombinant cell contains one or more nucleotide sequences as described above, and can produce one or more amino acid sequences of the human albumin specific binding polypeptide as described above. The recombinant bacterium can be bacteria or fungi, and the recombinant cell can be a virus or an animal cell, etc. Preferably, the recombinant bacterium includes Escherichia coli.
[0025] The fourth object of the present invention is to provide a complex, the complex includes the human albumin specific binding polypeptide and the nucleic acid molecule as described above; preferably, the human albumin specific binding polypeptide and the nucleic acid molecule are coupled to each other; preferably, the nucleic acid molecule is coupled to the end of the human albumin specific binding polypeptide. In this scheme, the nucleic acid molecule is a macromolecule that needs to use the human albumin specific binding polypeptide as a carrier to extend its half-life in vivo. The macromolecule is preferably but not limited to at least one of a molecule with pharmaceutical activity, a molecule with a labeling effect, and a molecule with a targeting effect. The coupling can be connected by covalent bonds or non-covalent bonds.
[0026] The fifth object of the present invention is a fusion protein, which includes the human albumin specific binding polypeptide and interferon protein as described above, and the human albumin specific binding polypeptide is connected to the N-terminus of the interferon protein.
[0027] In this scheme, the screened human albumin-specific binding polypeptide is connected to the N-terminus of interferon, and a vector is constructed to express the human albumin-specific binding polypeptide-interferon fusion protein. The obtained fusion protein has the activity of interferon, and the in vivo half-life of interferon is greatly prolonged, which can improve the therapeutic effect on viral infection.
[0028] The present invention uses the screened HSA specific binding polypeptide as a carrier, fuses human interferon with it, and prepares HSA specific binding polypeptide-human interferon fusion protein, which has the activity of interferon and can greatly prolong the half-life of human interferon.
[0029] In a further embodiment, the interferon protein is selected from interferon-α, interferon-β, interferon-γ and homologous interferons.
[0030] The sixth object of the present invention is to provide a method for preparing the fusion protein as described above, comprising the following steps:
[0031] (1) connecting the nucleotide sequence of human albumin specific binding polypeptide to the N-terminus of the interferon nucleotide sequence, constructing it into a target vector, and obtaining a recombinant vector;
[0032] (2) transferring the recombinant vector into the target strain and screening to obtain the recombinant bacteria;
[0033] (3) Fermenting and culturing the engineered bacteria, collecting and lysing the bacteria, and purifying to obtain a fusion protein comprising a human albumin-specific binding polypeptide and interferon.
[0034] Further specific plans include:
[0035] The key to prolonging the half-life of protein drugs by HSA adhesion method is to select HSA-specific binding peptides with specificity and high affinity. The steps are as follows: 1) Based on domestic and foreign patent information and public literature, a group of proteins or peptides that can specifically bind to human albumin are screened, and the spatial structural characteristics of HSA-specific binding peptides and the surface charge of human albumin are analyzed by bioinformatics methods to design a series of new peptide molecules; 2) Direct synthesis is performed by chemical synthesis; 3) Surface Plasmon Resonance (SPR) technology is used to determine the affinity of peptide molecules with HSA, and HSA-binding peptides that can bind to HSA with high binding force are selected. After the above steps, we screened out 3 peptide sequences, named antiHSA-1, antiHSA-2, and antiHSA-3.
[0036] According to the codon preference of E. coli, the corresponding nucleotide molecules were designed to encode the amino acid sequences of antiHSA-1, antiHSA-2, and antiHSA-3 respectively. The selected antiHSA peptides were connected to the N segment of IFNα-2b to form the fusion protein antiHSA-x-IFNα-2b (here x refers to the numbers 1, 2, 3, that is, antiHSA-x-IFNα-2b can refer to any one of antiHSA-1-IFNα-2b, antiHSA-2-IFNα-2b, and antiHSA-3-IFNα-2b). The antiHSA-x sequence and the IFNα-2b sequence were spliced together (antiHSA-x-IFNα-2b), constructed into the plasmid vector pET-32a(+), and transformed into the host bacteria BL21(DE3) to express the fusion protein antiHSA-x-IFNα-2b. After purification by Ni column, pure protein antiHSA-x-IFNα-2b was obtained.
[0037] The antiHSA-x-IFNα-2b obtained above was further evaluated by animal pharmacokinetic test. To prove the advanced nature of the present invention, the unfused IFNα-2b was used as the control group throughout the experiment.
[0038] The specific scheme of the present invention also includes repeating the above experiment by replacing IFNα-2b with IFNβ and IFNγ to prove that the specific binding polypeptide of the present invention can prolong the half-life of IFNβ and IFNγ.
[0039] The seventh objective of the present invention is to provide the use of the human albumin-specific binding polypeptide, biomaterial and fusion protein as described above in the preparation of protein drugs with extended half-life.
[0040] After adopting the above technical solution, the present invention has the following beneficial effects compared with the prior art:
[0041] 1. The present invention provides three screened human albumin binding polypeptides and amino acid sequences. These human albumin specific binding polypeptides are easy to prepare, have a small molecular weight, and have high HSA adhesion; and the specific binding polypeptides can be used as carriers to increase the half-life of the target protein in vivo and have a wide range of applications.
[0042] 2. The present invention adopts a fusion protein formed by the screened human albumin specific binding polypeptide and interferon, which has the activity of interferon and can greatly prolong the half-life of human interferon, thereby improving the therapeutic effect on viral infection.
[0043] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:
[0045] Figure 1 This is a blood activity-time curve of IFNα-2b and antiHSA-1-IFNα-2b, antiHSA-2-IFNα-2b, and antiHSA-3-IFNα-2b fusion proteins.
[0046] It should be noted that these drawings and textual descriptions are not intended to limit the conceptual scope of the present invention in any way, but are intended to illustrate the concept of the present invention for those skilled in the art by referring to specific embodiments. DETAILED DESCRIPTION
[0047] In order to more clearly explain the overall concept of the present application, the following is described in detail in conjunction with the accompanying drawings of the specification by way of embodiment. In the following description, a large number of specific details are provided to provide a more thorough understanding of the present invention. However, it is obvious to those skilled in the art that the present invention can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present invention, some technical features well known in the art are not described.
[0048] If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or conditions recommended by the manufacturer.
[0049] Unless otherwise specified, in the following embodiments, the reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.
[0050] Embodiment 1
[0051] (1) Screening of HSA-binding peptides
[0052] According to domestic and foreign patents and literature reports, a group of HSA-specific binding peptides that can specifically bind to human albumin were screened. The spatial structural characteristics of HSA-specific binding peptides and the surface charge of human albumin were analyzed using bioinformatics methods to design a series of new peptide molecules; direct synthesis was performed using chemical synthesis; the affinity of peptide molecules to HSA was determined using surface plasmon resonance technology (SPR) to select HSA-specific binding peptides that can bind to HSA with high binding force. After the above steps, we screened out 3 peptide sequences (as shown in Table 1), namely antiHSA-1, antiHSA-2, and antiHSA-3.
[0053] Then, according to the codon preference of E. coli, corresponding nucleotide molecules were designed, corresponding to the amino acid sequences of antiHSA-1, antiHSA-2, and antiHSA-3 respectively.
[0054] Table 1 AntiHSA sequences and affinity to human serum albumin
[0055] name Relative affinity μM Amino acid sequence Nucleotide sequence antiHSA-1 0.69 GFTFSSYA (SEQ ID NO: 1) GGTTTTACCTTTAGCAGCTATGCA (SEQ ID NO: 4) antiHSA-2 0.68 GFTFSSGA (SEQ ID NO: 2) GGTTTTACCTTTAGCAGCGGTGCA (SEQ ID NO: 5) antiHSA-3 0.81 GFTFFGMS (SEQ ID NO: 3) GGCTTTACCTTTTTCGGTATGAGC (SEQ ID NO: 6)
[0056] Embodiment 2
[0057] Preparation of fusion protein antiHSA-x-IFNα-2b
[0058] Here, x refers to the numbers 1, 2, and 3. That is, antiHSA-x-IFNα-2b can refer to any one of antiHSA-1-IFNα-2b, antiHSA-2-IFNα-2b, and antiHSA-3-IFNα-2b.
[0059] (1) Construction of vector and recombinant engineering bacteria
[0060] The three antiHSA peptides screened above were connected to the N segment of IFN to form the fusion protein antiHSA-x-IFNα-2b. Specifically, the antiHSA-x and IFNα-2b gene sequences were spliced together (antiHSA-x-IFNα-2b), and the whole gene was synthesized and constructed into the plasmid vector pET-32a(+) (purchased from Hunan Fenghui Biotechnology Co., Ltd.), and then transformed into competent cells BL21(DE3) (purchased from Shanghai Maokang Biotechnology Co., Ltd.), and genetically engineered bacteria were obtained through restriction digestion and sequencing.
[0061] IFNα-2b was directly constructed into pET-32a(+) as a control of the present invention. The gene sequence of IFNα-2b is shown in SEQ ID NO:7.
[0062] (2) Fermentation and cultivation of engineered bacteria
[0063] The culture medium formula used in this example is:
[0064] LB medium formula: peptone 10g / L, yeast extract powder 5g / L, sodium chloride 10g / L, ampicillin 100mg / L.
[0065] Trace element formula: ferrous sulfate heptahydrate 2g / L, manganese sulfate 0.52g / L, zinc sulfate 0.75g / L, cobalt chloride 0.13g / L, copper sulfate 0.1g / L, sodium molybdate 0.13g / L, calcium chloride dihydrate 8.37g / L.
[0066] Basic culture medium formula: glucose 2g / L, yeast powder 12g / L, potassium dihydrogen phosphate 15g / L, magnesium sulfate 0.25g / L, trace elements 10mL / L.
[0067] Feed medium formula: trace elements 100mL / L, glucose 400g / L, yeast powder 100g / L, magnesium sulfate 15.5g / L.
[0068] The engineered bacteria obtained above were inoculated into LB medium at a 1% inoculum and cultured at 37°C and 220 rpm in a shaking incubator until OD 600 ≥1.2, obtain seed solution; transfer the seed solution to a 50L fermenter containing 25L basal medium at a 5% inoculation rate, set the temperature to 37°C, ventilation to 25L / min, pH to 7.0, pressure to 0.050Mpa, speed to 300rpm, and control mode to automatic. During fermentation, adjust the speed and ventilation to control the dissolved oxygen to more than 30%. When OD 600 When it stops growing, start feeding; when OD 600 When OD ≥30, stop feeding, lower the tank temperature to 20℃ within 1 hour, add IPTG to a final concentration of 0.5mmol / L for induction culture, observe the change of dissolved oxygen, continue feeding, and control the feeding rate to keep the dissolved oxygen content at about 30%. 600 When the wet weight stops increasing, the material is collected and can be put into the tank.
[0069] (3) Protein sample separation and purification
[0070] The fermentation broth was centrifuged at 8000rpm for 20min to collect the bacteria, and purified water was added at 1:10 (m / v) to wash and centrifuge twice; the bacteria were then resuspended in 20mM PB buffer (pH7.4) at 1:10 (m / v), and ultrasonically broken in an ice bath; the broken product was centrifuged at 4℃ and 12000rpm for 15min, and the supernatant was filtered through a 0.45µm filter membrane; the sample was loaded onto a Ni-NTA affinity chromatography column, eluted with PB buffer (pH7.4) containing 500mM imidazole, and the elution peak was collected. The fusion protein separated and purified by the above chromatographic column was detected by SDS-PAGE gel electrophoresis, and the results were all above 90%.
[0071] Example 3 Identification of fusion protein
[0072] 1. Activity detection of the fusion protein antiHSA-x-IFNα-2b (x here refers to the numbers 1, 2, 3, that is, antiHSA-x-IFNα-2b can refer to any one of antiHSA-1-IFNα-2b, antiHSA-2-IFNα-2b, and antiHSA-3-IFNα-2b).
[0073] According to the cytopathic inhibition method in the interferon biological activity assay in General Rule 3523 of Part III of the 2020 edition of the Pharmacopoeia of the People's Republic of China, the biological activity of the fusion interferon was determined, and the specific activity test results are shown in Table 2.
[0074] The results show that the antiHSA fused IFNα-2b obtained by the present invention has a relatively ideal specific activity.
[0075] Table 2 Specific activity of AntiHSA fused with IFNα-2b
[0076]
[0077] 2. Pharmacokinetic study of the fusion protein antiHSA-x-IFNα-2b (x here refers to the numbers 1, 2, 3, that is, antiHSA-x-IFNα-2b can refer to any one of antiHSA-1-IFNα-2b, antiHSA-2-IFNα-2b, and antiHSA-3-IFNα-2b).
[0078] Twenty-four adult SD rats weighing about 290 g were selected and divided into four groups of six rats, half male and half female. Each group was injected with 7.25×10 6 IU of IFNα-2b and the above-mentioned AntiHSA-x-IFNα-2b fusion protein; blood was collected from the rat tail vein at 0, 0.5, 1, 1.25, 1.5, 2, 4, 6, 8, 12, 14, 16, 18, 20, 22, and 24 hours, and serum was collected to detect the biological activity of interferon retained in the serum. The "blood drug activity-time curve" was drawn and the data was fitted using software (such as Figure 1 The pharmacokinetic parameters were analyzed (Table 3).
[0079] Table 3 Pharmacokinetic parameters of IFNα-2b and anti-HSA fused IFNα-2b
[0080]
[0081] The results showed that the half-life of IFNα-2b was 1 / 2β The t of the fusion protein AntiHSA-1-IFNα-2b was 1.82 h. 1 / 2β The t of AntiHSA-2-IFNα-2b was 3.53 h. 1 / 2β The t of AntiHSA-3-IFNα-2b was 3.61 h. 1 / 2β It is 4.25h, indicating that the half-life of AntiHSA fused IFNα-2b is significantly prolonged compared with natural IFNα-2b.
[0082] Example 4 Preparation and identification of fusion protein antiHSA-x-IFNβ
[0083] Here, x refers to the numbers 1, 2, and 3, that is, antiHSA-x-IFNβ can refer to any one of antiHSA-1-IFNβ, antiHSA-2-IFNβ, and antiHSA-3-IFNβ.
[0084] The interferon IFNα-2b in Examples 2 and 3 was replaced by IFNβ, and the experimental steps of Examples 2 and 3 were repeated. The gene sequence of IFNβ is shown in SEQ ID NO: 8. The identification results are shown in Tables 4 and 5.
[0085] Table 4 Specific activity of AntiHSA fused with IFNβ
[0086]
[0087] Table 5 Pharmacokinetic parameters of IFNβ and anti-HSA fused IFNβ
[0088]
[0089] As shown in Tables 4 and 5, the specific activity of the fused interferon IFNβ was good and the half-life was prolonged.
[0090] Example 5 Preparation and identification of fusion protein antiHSA-x-IFNγ
[0091] Here, x refers to the numbers 1, 2, and 3, that is, antiHSA-x-IFNγ can refer to any one of antiHSA-1-IFNγ, antiHSA-2-IFNγ, and antiHSA-3-IFNγ.
[0092] The interferon IFNα-2b in Examples 2 and 3 was replaced by IFNγ, and the experimental steps of Examples 2 and 3 were repeated. The gene sequence of IFNγ is shown in SEQ ID NO: 9. The identification results are shown in Tables 6 and 7.
[0093] Table 6 Specific activity of AntiHSA fused with IFNγ
[0094]
[0095] Table 7 Pharmacokinetic parameters of IFNγ and antiHSA fused IFNγ
[0096]
[0097] As shown in Tables 6 and 7, the specific activity of the fused interferon IFNγ was good and the half-life was prolonged.
[0098] It is further explained that the AntiHSA provided by the present invention can increase the half-life of the target protein it carries in vivo.
[0099] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.
Claims
1. A human albumin-specific binding polypeptide, characterized in that: The amino acid sequence of the human albumin specific binding polypeptide is selected from at least one of the sequences shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO:
3.
2. A nucleic acid encoding the human albumin-specific binding polypeptide according to claim 1.
3. The nucleic acid according to claim 2, characterized in that The nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1 is shown in SEQ ID NO: 4; Or, the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:2 is shown in SEQ ID NO:5; Or, the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:3 is shown in SEQ ID NO:
6.
4. Use of the human albumin-specific binding polypeptide according to claim 1 in the preparation of an interferon drug with a prolonged half-life.
5. A biomaterial, characterized in that: The biological material is selected from any one of the following 1) to 2): 1) A vector having one or more nucleic acids according to claim 2 or 3; 2) A recombinant cell capable of producing one or more of the human albumin-specific binding polypeptides as claimed in claim 1, and / or containing one or more of the nucleic acids as claimed in claim 2 or 3.
6. Use of the biomaterial as claimed in claim 5 in the preparation of an interferon drug with a prolonged half-life.
7. A fusion protein, characterized in that The fusion protein is composed of the human albumin specific binding polypeptide according to claim 1 and interferon protein, and the human albumin specific binding polypeptide is connected to the N-terminus of the interferon protein.
8. The fusion protein according to claim 7, characterized in that The interferon protein is selected from one or more of interferon-α, interferon-β or interferon-γ.
9. A method for preparing the fusion protein according to any one of claims 7 to 8, characterized in that: The following steps are involved: (1) Connecting the nucleotide sequence of human albumin-specific binding polypeptide to the 5' end of the interferon nucleotide sequence, constructing it into the target body, and obtaining a recombinant vector; (2) Transferring the recombinant vector into the target strain and screening to obtain the recombinant bacteria; (3) Fermenting and culturing the engineered bacteria, collecting and lysing the bacteria, and purifying to obtain a fusion protein comprising a human albumin-specific binding polypeptide and interferon.
10. Use of the fusion protein according to any one of claims 7 to 8 in the preparation of an interferon drug with a prolonged half-life.
